Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW7J9D
|
|||
| Drug Name |
TB006
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
TrueBinding
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis A virus cellular receptor 2 (TIM3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05476783) A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients Who Have Completed Protocol TB006AD2102 and in De Novo Patients With Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of TrueBinding | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.